Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Starting dosage 0.25 mg once per week 3 mg once per day 1.5 mg once per day Maintenance dosage 0.5 to 2 mg once per week 7 to 14 mg once per day 4 to 9 mg once per day Given by self self self ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Taspoglutide was administered subcutaneously before breakfast once a week. Exenatide was injected as per prescribing information within a 60-min period before the morning and evening meals.

You will start this dose 1 week after stopping Ozempic. If your dose of Ozempic is either 0.25 mg, 1 mg, or 2 mg once per week, there is no recommended dose of Rybelsus formulation R1 to switch to.

The recommended dosage of Bydureon weight loss is 2 mg injected subcutaneously (under the skin) once a week. Bydureon comes in a single-use pen device that is pre-filled with the medication. Su Tang ...

The Nexon EV reigns triumphant over the Windsor in our rolling acceleration test. From 20-80kph, the Tata EV outperformed the Windsor by 0.2 seconds. In the 40-100kph dash, the gap widened further ...

From the March/April 2025 issue of Car and Driver. You'd think the sight of a new MG might attract more attention, whether it was spied carving up the winding roads of rural Scotland or whizzing ...

MG Windsor price range is Rs 13.50 lakh and Rs 15.50 lakh (ex-showroom) Battery-as-a-Service (BAAS) option reduces initial cost by Rs 3.5 lakh Battery warranty & car warranty: 8 years/1.6 lakh km ...

No evidence seen to support GLP-1 receptor agonist exenatide as disease-modifying ... assigned to receive extended-release exenatide 2 mg by subcutaneous pen injection once per week over 96 ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield ... receive extended-release exenatide 2 mg by subcutaneous pen injection once ...

Study participants (n=194) were randomly assigned 1:1 to receive subcutaneous exenatide extended-release 2mg or placebo once weekly for 96 weeks. The primary endpoint was the Movement Disorder ...